Wyeth Pharmaceuticals and Solvay Pharmaceuticals have entered into a new neuroscience discovery, co-development, and co-commercialization agreement. The two companies entered into development and commercialization agreements in April 2004 for bifeprunox and other neuroscience compounds. Under this collaboration, an NDA was submitted in October 2006 to the FDA for bifeprunox for the treatment of schizophrenia. Two additional clinical stage neuroscience development projects — part of the...